GlobeNewswire

Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin showed non-inferiority when compared to intravenous formulations for people with HER2-positive breast cancer

Share
  • New fixed-dose combination is administered under the skin in just minutes, significantly reducing the time spent receiving treatment
  • Data will be submitted to health authorities around the world, including the US Food and Drug Administration and European Medicines Agency
  • Results will be presented at an upcoming medical meeting

Basel, 13 September 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the phase III FeDeriCa study met its primary endpoint. The study showed a new investigational fixed-dose combination (FDC) of Perjeta® (pertuzumab) and Herceptin® (trastuzumab), administered by subcutaneous (SC) injection in combination with intravenous (IV) chemotherapy, demonstrated non-inferior levels of Perjeta in the blood (pharmacokinetics) compared to standard IV infusion of Perjeta plus Herceptin and chemotherapy in people with HER2-positive early breast cancer (eBC). The safety profile of the FDC of Perjeta and Herceptin was consistent with that of Perjeta and Herceptin administered intravenously.1, 2

“With this single injection under the skin, people with HER2-positive breast cancer receiving Perjeta and Herceptin can have a faster treatment option,” said Sandra Horning, MD, Roche’s Chief Medical Officer and Head of Global Product Development. “Our medicines have helped millions of people living with HER2-positive breast cancer and this latest development is particularly exciting as, for the first time, we have combined two therapeutic antibodies as a single subcutaneous formulation.”

SC administration of the FDC takes approximately 8 minutes for the initial loading dose, and approximately 5 minutes for each subsequent maintenance dose. This is compared to approximately 150 minutes for infusion of a loading dose of Perjeta and Herceptin using the standard IV formulations, and between 60-150 minutes for subsequent maintenance infusions for the combination.1, 2, 3

Full data from the FeDeriCa study will be submitted for presentation at an upcoming medical meeting and to health authorities around the world.

About the FeDeriCa study
FeDeriCa is an international, multi-centre, two-arm, randomised, open-label, phase III study evaluating the pharmacokinetics, efficacy and safety of SC injection of the FDC of Perjeta and Herceptin in combination with chemotherapy, compared with standard IV infusions of Perjeta and Herceptin in combination with chemotherapy in people with HER2-positive eBC who are being treated in the neoadjuvant (before surgery) and adjuvant (after surgery) settings.4 The primary endpoint of the study is minimum levels of Perjeta in the

blood during a given dosing interval (Ctrough). Secondary endpoints include safety; minimum levels of Herceptin in the blood during a given dosing interval (Ctrough); and total pCR, meaning there is no tumour tissue detectable at the time of surgery.4

About the FDC of Perjeta and Herceptin
The FDC of Perjeta and Herceptin is a new SC formulation that combines Perjeta and Herceptin with Halozyme Therapeutics’ Enhanze® drug delivery technology.

Trastuzumab in the FDC is the same monoclonal antibody as in IV Herceptin and pertuzumab is the same monoclonal antibody as in IV Perjeta. The mechanisms of action of Perjeta and Herceptin are believed to complement each other as both bind to the HER2 receptor, but to different places.5 The combination of Perjeta and Herceptin is thought to provide a more comprehensive, dual blockade of the HER signaling pathways.5

The standard IV formulation of Perjeta in combination with IV Herceptin and chemotherapy (the Perjeta-based regimen) is approved in over 100 countries for the treatment of both early and metastatic HER2-positive breast cancer. In the neoadjuvant eBC setting, the Perjeta-based regimen has been shown to almost double the rate of pCR compared to Herceptin and chemotherapy.6 Additionally, the combination has been shown to significantly reduce the risk of recurrence of invasive disease or death in the adjuvant eBC setting.7 In the metastatic setting, the combination has shown an unprecedented survival benefit in previously untreated (first-line) patients with HER2-positive metastatic breast cancer.8

Halozyme’s Enhanze drug delivery technology may enable and optimise SC drug delivery for appropriate co-administered therapeutics. The technology is based on a proprietary recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that temporarily degrades hyaluronan – a glycosaminoglycan or chain of natural sugars in the body, to aid in the dispersion and absorption of other injected therapeutic drugs.9

About Roche’s medicines for HER2-positive breast cancer
Roche has been leading research into the HER2 pathway for over 30 years and is committed to improving the health, quality of life and survival of people with both early and metastatic HER2-positive disease. HER2-positive breast cancer is a particularly aggressive form of the disease that affects approximately 15-20% of patients.10 Roche has developed three innovative medicines that have helped transform the treatment of HER2-positive breast cancer: Herceptin (trastuzumab), Perjeta (pertuzumab) and Kadcyla® (trastuzumab emtansine). Eligibility for treatment with Roche’s HER2-targeted medicines is determined via a diagnostic test which identifies people who will likely benefit from these medicines at the onset of their disease.

About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the tenth consecutive year, Roche has been recognised as the most sustainable company in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2018 employed about 94,000 people worldwide. In 2018, Roche invested CHF 11 billion in R&D and posted sales of CHF 56.8 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] European Medicines Agency. Summary of Product Characteristics for Herceptin. [Internet; cited 2019 September]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000278/WC500074922.pdf.
[2] European Medicines Agency. Summary of Product Characteristics for Perjeta. [Internet; cited 2019 September]. Available from: https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf.
[3] US Food and Drug Administration. Prescribing Information for Herceptin. [Internet; cited September 2019]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5250lbl.pdf.
[4] Clinical trials.gov. A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer. [Internet; cited September 2019]. Available from: https://clinicaltrials.gov/ct2/show/NCT03493854.
[5] Baselga J, Swain SM. Nat Rev Cancer 2009;9:463-75.
[6] Gianni L, et al. Lancet Oncol. 2012;13(1):25-32.
[7] Minckwitz G, et al. N Engl J Med. 2017;DOI:10.1056/NEJMoa1703643.
[8] Swain SM, et al N Engl J Med. 2015; DOI:10.1056/NEJMoa1413513.
[9] Halozyme. Enhanze® Drug Delivery Technology. [Internet; cited 2019 September]. Available from: https://www.halozyme.com/enhanze/overview/default.aspx.
[10] Wolff AC, et al. J Clin Oncol. 2013;31(31):3997-4013.

Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com
- Nicolas Dunant (Head)
- Patrick Barth
- Ulrike Engels-Lange
- Daniel Grotzky
- Karsten Kleine
- Nathalie Meetz
- Barbara von Schnurbein

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Vostok Emerging Finance depository receipt buy-back14.10.2019 09:20:00 CESTPress release

Stockholm, Oct. 14, 2019 (GLOBE NEWSWIRE) -- Vostok Emerging Finance Ltd’s (“VEF” or “the Company”) has between October 7 and October 11, 2019 repurchased 500,000 Swedish Depository Receipts (SDRs), at an average price of SEK 2,70, corresponding to a 21% discount to the latest reported NAV of the Company. These repurchased SDRs represent 0,08% of the total number of outstanding ordinary SDRs of Vostok Emerging Finance. The Company currently holds 5,016,218 repurchased SDRs. The total number of outstanding SDRs of the Company, excluding repurchased SDRs, is 656,479,777. For further information please contact: Henrik Stenlund, CFO: +46 (0) 8-545 015 50 Vostok Emerging Finance is an investment company with the goal of investing in early stage modern financial services companies across emerging and frontier markets. VEF trades in Sweden on Nasdaq First North Growth Market under the ticker VEMF SDB. Vostok Emerging Finance’s Certified Adviser on Nasdaq First North Growth Market is Pareto Se

Vostok Emerging Finance depository receipt buy-back14.10.2019 09:20:00 CESTPressemelding

Stockholm, Oct. 14, 2019 (GLOBE NEWSWIRE) -- Vostok Emerging Finance Ltd’s (“VEF” or “the Company”) has between October 7 and October 11, 2019 repurchased 500,000 Swedish Depository Receipts (SDRs), at an average price of SEK 2,70, corresponding to a 21% discount to the latest reported NAV of the Company. These repurchased SDRs represent 0,08% of the total number of outstanding ordinary SDRs of Vostok Emerging Finance. The Company currently holds 5,016,218 repurchased SDRs. The total number of outstanding SDRs of the Company, excluding repurchased SDRs, is 656,479,777. For further information please contact: Henrik Stenlund, CFO: +46 (0) 8-545 015 50 Vostok Emerging Finance is an investment company with the goal of investing in early stage modern financial services companies across emerging and frontier markets. VEF trades in Sweden on Nasdaq First North Growth Market under the ticker VEMF SDB. Vostok Emerging Finance’s Certified Adviser on Nasdaq First North Growth Market is Pareto Se

Valberedning inför årsstämma 202014.10.2019 09:00:00 CESTPressemelding

Hexatronic Group AB (publ) 556168-6360 Pressmeddelande 14 oktober 2019 Valberedning inför årsstämma 2020 Till ledamöter i Hexatronic Groups valberedning har utsetts: Mark Shay, representerar Accendo Capital Staffan Ringvall, representerar Handelsbanken Fonder Jonas Nordlund, representerar sig själv Erik Selin, representerar Chirp AB Anders Persson, adjungerad, i egenskap av styrelseordförande i Hexatronic Group Mark Shay valdes till ordförande i valberedningen. Valberedningen har utsetts i enlighet med den instruktion som fastställdes vid årsstämman 2019. Valberedningen representerar tillsammans ca 32 procent av röstetalet för samtliga röstberättigade aktier i bolaget. Valberedningens förslag kommer att presenteras i kallelsen till årsstämman 2020 samt på bolagets hemsida, www.hexatronicgroup.com. Aktieägare som önskar lämna förslag till valberedningen inför årsstämman 2020 kan göra detta genom e-post till lennart.sparud@hexatronic.com (rubricera ”Till Valberedningen”). Göteborg 14 okt

Share Buyback Programme: Week ending 11 October 201914.10.2019 09:00:00 CESTPress release

EUROCASTLE INVESTMENT LIMITED FOR IMMEDIATE RELEASE Contact: International Administration Group (Guernsey) Limited Company Administrator Attn: Mark Woodall Tel: +44 1481 723450 Share Buyback Programme: Transactions in week ending 11 October 2019 Guernsey, 14 October 2019 – Eurocastle Investment Limited (“Eurocastle” or the “Company”) today announces that between 7 October 2019 and 11 October 2019, under its fifth non-discretionary share buyback programme with Liberum Capital Limited (acting as the Company's broker) announced on 9 August 2019 and commenced on 16 September 2019 (the “Fifth Buyback Programme”), it bought back 11,584 of its ordinary shares at an average price of €7.32 per ordinary share. The purchased shares will all be held as treasury shares. The purpose of the share buyback programme is to reduce the share capital of the Company and the programme is executed in compliance with the provisions of Regulation (EU) No 596/2014 of the European Parliament and of the Council of

Oboya får order på blomster- och logistikvagnar om 4,2 MSEK14.10.2019 08:08:00 CESTPressemelding

Oboya Horticulture Industries AB (publ) (”Oboya” eller ”Bolaget”) har genom sitt helägda dotterbolag Oboya Metal Qingdao Co. Ltd i Qingdao, Kina fått order på blomster- och logistikvagnar från kunder i Australien och Colombia. Det sammanlagda ordervärdet uppgår till cirka 421,1 TUSD, motsvarande cirka 4,2 MSEK. Genom dessa beställningar fortsätter Oboya ta marknadsandelar på den internationella odlingsmarknaden och cementerar sin position som en totalleverantör. Bolaget har genom åren erhållit flera order på blomster- och logistikvagnar från kunder i Europa, Nord- och Sydamerika, Afrika och Kina. Oboya har blivit en ledande producent inom produktsegmentet blomster- och logistikvagnar och erbjuder konkurrenskraftiga priser genom direktleveranser från Bolagets fabriker. Beställningarna kommer från ledande odlings- och logistikföretag i Australien och Colombia. Blomster- och logistikvagnarna kommer att användas för såväl effektiv transport som exponering av växter eller blommor i butik. D

Oboya receives orders for flower- and logistics trolleys of SEK 4,2 million14.10.2019 08:08:00 CESTPress release

Oboya Horticulture Industries AB (publ) ("Oboya" or "The Company") has through its wholly owned subsidiary Oboya Metal Qingdao Co. Ltd. in Qingdao, China received orders for flower- and logistics trolleys from customers in Australia and Colombia. The total order value amounts to approximately USD 421.1 thousand, corresponding to approximately SEK 4.2 million. Through these orders, Oboya continues to take market shares in the international cultivation market and cement its position as a total supplier. Over the years, the company has received several orders for flower- and logistics trolleys from customers in Europe, North- and South America, Africa and China. Oboya has become a leading producer of the product segment in flower- and logistics trolleys and offers competitive prices through direct deliveries from the Company's factories. The orders come from leading cultivation and logistics companies in Australia and Colombia. The flower- and logistics trolleys will be used for efficient